Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
The effect of switching from originator infliximab to biosimilar infliximab in patients with sarcoidosis is unknown. The objective of this study is to investigate the effect of switching from Remicade<sup>®</sup> or Inflectra<sup>®</sup> to Flixabi<sup>®</sup> in...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/2/441 |